drugset / Trial / NCT06665425

PK,PD and DDI of Epaminurad and C2406 in Healthy Volunteers

NCT06665425

Phase 1 Completed 18 enrolled JW Pharmaceutical
NaSingle-groupOpen-labelTreatment

Summary

A Phase 1 Study to evaluate the safety, PK/PD, drug-drug interaction(DDI) of Epaminurad and C2406 in Healthy Volunteers

Timeline

Start
2025-03-24
Primary completion
2025-05-02
Completion
2025-09-04

Drugs

EvaluationDrugModalityDoseRoute
Subject C2406 Unknown 0.6 mg
Subject Epaminurad Small molecule 9 mg

Indications

No indication recorded.